Abbott Laboratories (ABT)

US — Healthcare Sector
Peers: NVO  MRK  NVS  TMO  MDT  BSX  SYK  AZN  UNH  GILD 

Automate Your Wheel Strategy on ABT

With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABT
  • Rev/Share 24.7688
  • Book/Share 29.2044
  • PB 4.4244
  • Debt/Equity 0.2657
  • CurrentRatio 1.8207
  • ROIC 0.188

 

  • MktCap 223718601660.0
  • FreeCF/Share 3.8927
  • PFCF 33.0212
  • PE 16.0039
  • Debt/Assets 0.16
  • DivYield 0.0184
  • ROE 0.2993

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ABT The Benchmark Company -- Buy -- $145 Oct. 10, 2025
Upgrade ABT Jefferies Hold Buy -- $145 July 18, 2025
Initiation ABT Leerink Partners -- Market Perform -- $143 June 16, 2025
Initiation ABT Oppenheimer -- Outperform -- $130 Oct. 8, 2024
Initiation ABT Piper Sandler -- Overweight -- $131 Sept. 19, 2024

News

Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
ABT
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott posts strong Q3 growth across key segments, but tariff pressures and weak Diagnostics weigh on near-term momentum.

Read More
image for news Abbott Q3 Earnings Review: Tariff, Diagnostics Cap Near-Term Gains
Abbott Laboratories' October Price Plunge Is a Signal to Buy
ABT
Published: October 17, 2025 by: MarketBeat
Sentiment: Negative

Abbott Laboratories' NYSE: ABT October price plunge is a signal to buy, as analyst and institutional trends suggest they, too, will be buying the stock. Analyst trends revealed by MarketBeat data include increasing coverage with newly initiated ratings appearing within days of the Q3 earnings release.

Read More
image for news Abbott Laboratories' October Price Plunge Is a Signal to Buy
Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth
ABT, APD, HSY, MSGE
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Positive

The Goldman Sachs Conviction List is a curated list of stocks that the firm's research team believes have a high likelihood of outperforming the market.

Read More
image for news Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds
ABT
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Negative

Abbott Laboratories delivered solid Q3 2025 results, with diversified growth across medical devices, nutrition, and branded generics offsetting diagnostics weakness. ABT's international presence and exposure to emerging markets drive structural growth, while its broad portfolio provides resilience amid global economic volatility. Tariffs and China remain key risks, but ABT's flexible supply chain and reduced China exposure help limit downside, with management actively shifting focus to other regions.

Read More
image for news Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
AAAU, ABT, BAR, DBP, DGL, GLD, GLDM, IAU, OUNZ, SGOL, UGL
Published: October 15, 2025 by: Benzinga
Sentiment: Neutral

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

Read More
image for news Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
ABT
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Neutral

Abbott Laboratories (NYSE:ABT ) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT Company Participants Michael Comilla - Vice President of Investor Relations. Robert Ford - Chairman of the Board, President & CEO Philip Boudreau - CFO & Executive VP of Finance Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Joshua Jennings - TD Cowen, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Joanne Wuensch - …

Read More
image for news Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
NVST or ABT: Which Is the Better Value Stock Right Now?
ABT, NVST
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Read More
image for news NVST or ABT: Which Is the Better Value Stock Right Now?
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
ABT
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.

Read More
image for news Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
ABT
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings
Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance
ABT
Published: October 15, 2025 by: Proactive Investors
Sentiment: Positive

Abbott Laboratories (NYSE:ABT) reported steady growth in the third quarter, with sales rising 6.9% to $11.37 billion, slightly below estimates of $11.4 billion, and adjusted earnings per share matching expectations at $1.30. The company's results were driven by broad-based strength across Abbott's medical devices and diagnostics businesses, even as COVID-19 testing-related revenue continued to normalize.

Read More
image for news Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance
Abbott (ABT) Q3 Earnings Meet Estimates
ABT
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) came out with quarterly earnings of $1.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.21 per share a year ago.

Read More
image for news Abbott (ABT) Q3 Earnings Meet Estimates
Worried Investors Should Look at the 5 Safest Dividend Kings Right Now
ABT, ADP, PG, SPGI, WMT
Published: October 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral

First, it was David Solomon from Goldman Sachs, then Jamie Dimon from J.P.

Read More
image for news Worried Investors Should Look at the 5 Safest Dividend Kings Right Now
Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings
ABT
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Neutral

Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Read More
image for news Wall Street's Insights Into Key Metrics Ahead of Abbott (ABT) Q3 Earnings
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
ABT
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
ABT
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Neutral

ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.

Read More
image for news Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
ABT
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Neutral

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read More
image for news Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
ABT, BSX
Published: September 30, 2025 by: Proactive Investors
Sentiment: Positive

UBS analysts are ‘Overweight' the healthcare equipment sector, with a Number One ranking on their total scorecard. In a note to clients on Tuesday, the analysts wrote that healthcare equipment has had the highest growth rate historically, excluding technology, at a 9% compound annual growth rate (CAGR) and the sector's earnings per share are now trading 10% below trend.

Read More
image for news Healthcare equipment stocks seen outperforming, ‘safer' than Big Pharma: analysts
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
ABT
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive

ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.

Read More
image for news Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
Abbott Hosts Conference Call for Third-Quarter Earnings
ABT
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral

ABBOTT PARK, Ill., Sept. 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2025 financial results on Wednesday, Oct. 15, before the market opens.

Read More
image for news Abbott Hosts Conference Call for Third-Quarter Earnings
1 Dividend King To Hold And 2 Worth Buying Now
ABT, FRT, PPG
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive

It's often said that cash is king, but I would take it one step further. Abbott Laboratories is an AA-rated Dividend King with healthy growth prospects but a rich valuation. I'm waiting for a pullback to the low-$120 range before upgrading back to a buy. Federal Realty owns top-notch properties in demographically thriving markets, possesses a conservatively leveraged balance sheet, and has the longest track record of dividend growth in REITdom.

Read More
image for news 1 Dividend King To Hold And 2 Worth Buying Now
Abbott Declares 407th Consecutive Quarterly Dividend
ABT
Published: September 19, 2025 by: PRNewsWire
Sentiment: Neutral

ABBOTT PARK, Ill., Sept. 19, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59 cents per share.

Read More
image for news Abbott Declares 407th Consecutive Quarterly Dividend
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
ABT
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Neutral

ABT's strong Nutrition, Diabetes Care and EPD growth fuel momentum, but macro and currency headwinds challenge its outlook.

Read More
image for news Is it the Right Time to Retain Abbott Stock in Your Portfolio?
Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
ABT
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Neutral

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
ABT
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
NVST vs. ABT: Which Stock Should Value Investors Buy Now?
ABT, NVST
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Read More
image for news NVST vs. ABT: Which Stock Should Value Investors Buy Now?
ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
ABT
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.

Read More
image for news ABT Stock Gains From Navitor's Expanded Indication Approval in Europe
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
ABT, EW
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors are showing growing interest in the rapidly expanding structural heart device market, which is expected to witness a compound annual growth rate (CAGR) of 13.5% between 2025 and 2033, according to Grand View Research. Abbott Laboratories ABT and Edwards Lifesciences EW are two key players with significant presence in this sector.

Read More
image for news ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
Best Dividend Aristocrats For September 2025
ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CB, CHD, CHRW, CINF, CL, CLX, CTAS, CVX, DOV, ECL
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.

Read More
image for news Best Dividend Aristocrats For September 2025
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
ABT
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive

ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.

Read More
image for news What's Driving Abbott's Gross Margin Growth Amid Macro Issues

About Abbott Laboratories (ABT)

  • IPO Date 1980-03-17
  • Website https://www.abbott.com
  • Industry Medical - Devices
  • CEO Robert B. Ford
  • Employees 114000

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.